CELC launches REVTORPYK for HR-positive, HER2-negative advanced breast cancer
Celcuity (CELC) says REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and market-access groundwork. Phase III studies are ongoing, and expanded manufacturing is planned.
REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and robust market access groundwork. Multiple phase III studies are ongoing in breast and prostate cancer, and expanded manufacturing is planned to support future growth.Based on Celcuity In…